--- title: "1.6 billion claim targets IMEIK, \"Youth Needle\" agency battle heats up" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/32853804.md" description: "The battle for the agency rights of AestheFill's "Youthful Needle" has entered a fierce stage. On the evening of August 11, *ST Su Wu (600200.SH) announced that its controlled subsidiary, Dato Medical Devices (Shanghai) Co., Ltd., has filed for arbitration with the Shenzhen Court of International Arbitration regarding the breach of contract by Regen Biotech, Inc. The company requests confirmation of the validity and continued performance of the "Exclusive Agency Agreement." If not supported, preliminary claims amount to RMB 1.6 billion in losses, and the case has been accepted and filed. Image source: Screenshot of Jiangsu Wuzhong's announcement. 2021..." datetime: "2025-08-12T09:03:14.000Z" locales: - [en](https://longbridge.com/en/topics/32853804.md) - [zh-CN](https://longbridge.com/zh-CN/topics/32853804.md) - [zh-HK](https://longbridge.com/zh-HK/topics/32853804.md) author: "[阿尔法工场](https://longbridge.com/en/profiles/5044766.md)" --- # 1.6 billion claim targets IMEIK, "Youth Needle" agency battle heats up The battle for the agency rights of AestheFill "Baby Face Needle" has entered a fierce stage. On the evening of August 11, \*ST Su Wu (600200.SH) announced that its subsidiary, Dato Medical Device (Shanghai) Co., Ltd., has filed an arbitration case with the Shenzhen Court of International Arbitration regarding the breach of contract by Regen Biotech, Inc. The company is requesting confirmation of the validity and continued performance of the "Exclusive Agency Agreement." If the request is not supported, preliminary claims for losses amount to RMB 1.6 billion, and the case has been accepted and filed. Source: Screenshot of Jiangsu Wuzhong's announcement In 2021, Jiangsu Wuzhong, through its subsidiary Wuzhong Aesthetics, took control of Dato Medical, which obtained the exclusive sales agency rights for AestheFill in mainland China from Regen until 2032, and this agreement was "irrevocable." The acquisition of this exclusive agency right allowed Jiangsu Wuzhong to secure a place in the medical aesthetics market. In 2024 alone, it contributed approximately RMB 326 million in revenue, with a gross profit of RMB 269 million, making it a key pillar of Jiangsu Wuzhong's performance in recent years. However, as the brand owner, Regen's revenue for the first three quarters of 2024 was only RMB 72.2311 million, with a net profit of RMB 29.5003 million. This contrast undoubtedly sowed the seeds of conflict, which erupted after the acquisition of Regen by the medical aesthetics giant Imeik Technology this year. Imeik Technology is the key variable that triggered this agency rights dispute. On July 2, Imeik Technology (300896.SZ) announced that its subsidiary, "Imeik International," had paid 95% of the consideration for the acquisition of REGEN Biotech, Inc. (Lizhen Biotechnology). On July 11, Imeik Technology and Regen changed the medical device registration agent for AestheFill in China from Dato Medical to Lizhen (Beijing) Biotechnology Co., Ltd., a subsidiary controlled by Regen. On July 20, Regen announced the launch of a new Chinese trademark for AestheFill: "Zhen Ai·Su Fei." On the evening of July 21, Jiangsu Wuzhong announced that the exclusive agency rights of its subsidiary Dato Medical had been unilaterally revoked. Source: Jiangsu Wuzhong's announcement From the announcement, it can be seen that Jiangsu Wuzhong's primary goal is to reclaim the exclusive agency agreement for AestheFill in mainland China. However, if the possibility of regaining the agency rights is slim, the RMB 1.6 billion in economic loss compensation could still offset some of Jiangsu Wuzhong's financial losses. Previously, industry insiders speculated that whether the termination was justified would depend on the relevant provisions of the agency agreement, the nature of the contract, and transaction practices. However, if Imeik Technology and Regen are found to have maliciously breached the contract, they may be required to compensate Jiangsu Wuzhong for "all potential profits during the remaining agency period." According to data from LeadLeo Research and the remaining eight years of the agency period, the potential compensation amount could far exceed the $190 million acquisition consideration. One week before the sudden termination, Jiangsu Wuzhong received administrative penalties from the China Securities Regulatory Commission (CSRC) for false records in its financial reports from 2020 to 2023. It was also subject to additional delisting risk warnings by the Shanghai Stock Exchange. Earlier this year, Jiangsu Wuzhong and its chairman, Qian Qunshan, were separately investigated by the CSRC for suspected violations of information disclosure regulations. With the situation precarious and the sudden loss of its agency rights—potentially its only "cash cow"—Jiangsu Wuzhong now has nothing left to lose. From a long-term perspective, the controversy surrounding Imeik Technology and Regen's "inconsistent actions and forced contract termination" could not only damage their reputation in the industry but also raise market doubts about the standardization of their products, leading consumers to switch to competitors like Aivlan and Suyancui. ### Related Stocks - [300896.CN](https://longbridge.com/en/quote/300896.CN.md)